The oncology community is mourning the loss of Dr. Maura L. Gillison, MD, PhD, a physician-scientist whose work fundamentally changed how doctors understand and treat head and neck cancers.
Dr. Gillison passed away on June 21, 2026, surrounded by her family. She was widely regarded as a giant in the field of head and neck oncology, and tributes have poured in from organizations including NRG Oncology and the RTOG Foundation, both of which issued statements expressing their condolences to her family, friends, and loved ones.
Dr. Gillison’s research career was defined by a discovery that reshaped an entire area of cancer medicine. She demonstrated that human papillomavirus, particularly the HPV-16 strain, was responsible for a distinct subset of head and neck cancers.
Before her findings, the medical community largely believed that tobacco and alcohol use were the only significant drivers of these diseases.
Her work established HPV as a separate and previously unrecognized cause, opening the door to new approaches in prevention, diagnosis, and treatment that have benefited countless patients in the years since.
A Career That Changed the Field
Colleagues and institutions describe Dr. Gillison’s impact as nothing short of transformative. Her research did not simply add a footnote to existing knowledge about head and neck cancer; it created an entirely new framework for understanding the disease.
By identifying HPV related cancers as a unique category, she helped pave the way for targeted screening efforts, vaccination strategies aimed at prevention, and treatment protocols tailored specifically to HPV positive patients, who often have different outcomes than those with cancers linked to tobacco and alcohol.
Her findings have influenced clinical guidelines around the world and continue to inform how oncologists approach diagnosis and treatment decisions today.
For many physicians and researchers in the field, her work represents one of the most significant advances in head and neck oncology in recent decades.
Tributes Pour In From the Oncology Community
Following news of her passing, NRG Oncology shared a heartfelt message honoring her legacy, noting the depth of her contributions to cancer research and expressing sympathy to those who knew her personally and professionally.
The RTOG Foundation also released a tribute, stating that the global oncology community feels the weight of this loss deeply and that her scientific legacy will continue to guide research and patient care for generations to come.
Both organizations emphasized that Dr. Gillison’s influence extended far beyond her own laboratory or clinic.
Her mentorship of younger researchers, her dedication to advancing the field, and her willingness to challenge long-held assumptions about cancer causation all contributed to a body of work that will likely be studied and built upon for years.
As the oncology community reflects on her life and career, many are highlighting not just her scientific achievements but also her character as a colleague, mentor, and friend.
Her passing leaves a void in the field, but her research continues to save lives through earlier detection, better prevention strategies, and more personalized treatment options for patients facing HPV associated head and neck cancers.
Dr. Gillison is remembered as a trailblazer whose curiosity and rigor changed the course of cancer research, and whose legacy will remain embedded in clinical practice for decades to come.
